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Abstract 
 
Question of the study.  The severe Z deficiency allele of α1-antitrypsin (Glu342Lys) results in the 
formation of polymers that are retained within hepatocytes.  It is unknown whether they are present in 
the plasma of individuals with α1-antitrypsin deficiency and if they are associated with any clinical 
phenotype.   
 
Methods.  We have used the anti-α1-antitrypsin polymer monoclonal antibody (2C1) to assess the 
presence of polymers in the plasma of: (i) 293 individuals with a mix of α1-antitrypsin genotypes, (ii) 
an individual with α1-antitrypsin deficiency who underwent liver transplantation and (iii) a cohort of 
244 individuals with PiZZ α1-antitrypsin deficiency.    
 
Results.  The presence of circulating polymers was 100% sensitive and 89% specific in identifying 
20 PiZZ α1-antitrypsin homozygotes in a mix of 293 α1-antitrypsin genotypes.  They clear following 
liver transplantation with a half-life estimated to be 30 hours.  Circulating polymers were present in 
every one of 244 individuals with PiZZ α1-antitrypsin deficiency with higher levels in men, 
individuals with airflow obstruction (-0.411 SE 0.116; p<0.0005) and those with COPD (adjusted OR 
3.6, 95% confidence interval 1.4-9.1). 
 
Answer to the question.  Circulating polymers of α1-antitrypsin are present in all individuals with PiZZ 
α1-antitrypsin deficiency and are associated with COPD. 
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Introduction 
 
Most individuals carry two wild-type M alleles of the SERPINA1 gene that encodes α1-antitrypsin 
[1, 2].  Ninety-five percent of severe deficiency of α1-antitrypsin results from the Z allele (Glu342Lys; 
denoted PiZZ in the homozygote) that causes newly synthesised protein to polymerise and be retained 
within hepatocytes [3, 4].  These polymers form the Periodic Acid Schiff (PAS) positive, diastase-
resistant inclusions that are present in all individuals with a Z allele and are associated with neonatal 
hepatitis, cirrhosis and hepatocellular carcinoma.  The concomitant lack of circulating α1-antitrypsin 
predisposes the Z α1-antitrypsin homozygote to early onset emphysema.  Polymers of α1-antitrypsin 
form within the lung as a result of local inflammation and exposure to cigarette smoke [5-8].  They 
have also been identified in the skin of an individual with α1-antitrypsin deficiency and panniculitis 
[9] and in a renal biopsy of an individual with α1-antitrypsin deficiency and vasculitis [10].  We have 
assessed whether polymers of α1-antitrypsin are present within serum and whether they are associated 
with clinical features in individuals with PiZZ α1-antitrypsin deficiency. 
 
 
Materials and Methods 
 
Subjects and cohorts 
 
Identification of circulating polymers in individuals with a mix of α1-antitrypsin genotypes (cohort 1) 
This cohort was used to establish whether the presence of circulating polymers could identify 
individuals with α1-antitrypsin deficiency.  293 individuals with a mix of SERPINA1 genotypes were 
identified from the Alpha-1 Foundation DNA and Tissue Bank.  These included the following α1-
antitrypsin genotypes (number): MM (200), MZ (20), ZZ (20), SZ (20), FZ (5), SS (3), MS (20), 
ZMheerlen (3) and ZMmalton (2).  No individual was receiving α1-antitrypsin augmentation therapy. 
 Clearance of polymers following liver transplantation 
A 54 year old man who was not part of either of the two cohorts presented with a 12 month history 
of peripheral oedema and was found to have a cirrhotic liver, portal hypertension and gastro-
oesophageal varices.  Investigation showed him to be a PiZZ α1-antitrypsin homozygote.  He had 
normal lung function.  His condition deteriorated, he developed episodes of encephalopathy and was 
admitted for orthotopic liver transplantation.  The procedure was prolonged by a large portal vein 
thrombus in the recipient and he developed reperfusion injury with hyperkalaemia that necessitated 3 
hours of intra-operative hemofiltration.  His post-operative care was subsequently uneventful and he 
was discharged home. 
 
The correlation of circulating polymers with clinical phenotypes (cohort 2) 
The Alpha-1 Antitrypsin Genetic Modifier Study is a multicentre study performed in collaboration 
with the Alpha-1 Foundation.  The design of this study has been described previously [11].  This 
cohort was used to determine whether circulating polymers are associated with any demographic or 
clinical phenotype in individuals with α1-antitrypsin deficiency. 
 
ELISA assay to detect polymers of α1-antitrypsin 
The ELISA assay used the 2C1 monoclonal antibody that detects only the polymeric conformer of 
α1-antitrypsin.  It does not detect monomeric M or Z α1-antitrypsin [12-14].  Briefly the plates were 
coated overnight with antigen purified rabbit polyclonal α1-antitrypsin antibody.  Standard (plasma 
purified Z α1-antitrypsin heated to form polymers [15]) and subject samples were diluted in blocking 
buffer and incubated overnight at 4°C.  The wells were washed and incubated with the 2C1 
monoclonal antibody diluted in blocking buffer.  Bound 2C1 antibody was detected with rabbit anti-
mouse IgG horseradish peroxidase antibody.  Horseradish peroxidase activity was subsequently 
measured in a plate reader at 450 nm.  The assays were performed by investigators who were blind to 
the genotypes and clinical features of the subjects.  The inter-assay coefficient of variation was 11.7% 
and polymer concentrations are reported in micrograms/millilitre.  Values were log transformed for 
regression analysis.  The specificity of the antibody was confirmed by using it to immunoprecipitate 
polymers from the plasma of individuals with and without a positive signal on ELISA.  Sepharose G 
beads were incubated with the 2C1 monoclonal antibody and then with 1 mL of a plasma sample 
containing α1-antitrypsin polymer (PiZZ genotype) or a plasma sample containing no polymer 
(PiMM).  The precipitated protein was eluted by DTT, and analysed with SDS-PAGE followed by 
Western blot using rabbit polyclonal antibody to α1-antitrypsin.  
 
Statistical analysis 
The α1-antitrypsin Genetic Modifiers Study cohort (cohort 2) was used to establish whether the 
levels of circulating polymers correlated with any demographic or clinical phenotype in individuals 
with PiZZ α1-antitrypsin deficiency.  In this analysis linear regression was performed to identify 
factors that predicted polymer levels.  A multivariate analysis included predictors at the p<0.1 level in 
the univariate analysis.  All computations were performed using the SAS statistical package (SAS 
Statistical Institute, North Carolina, USA). 
 
Ethical approval 
The study was approved by local Institutional Review Boards and all subjects provided informed 
consent. 
 
 
Results 
 
Identification of circulating polymers in individuals with a mix of α1-antitrypsin genotypes (cohort 1) 
The presence of circulating polymers was evaluated in cohort 1 for its ability to identify individuals 
with α1-antitrypsin deficiency.  It was 100% sensitive and 89% specific in detecting 20 PiZZ α1-
antitrypsin homozygotes in a mix of 293 genotypes (Fig. 1a).  It was 70% sensitive and 99% specific 
in identifying the Z allele (PiXZ where X is any allele other than Z).  A low signal was detected in 1 
of 200 individuals with a normal α1-antitrypsin phenotype (PiMM) but in none of the 3 SS 
homozygotes who have mild α1-antitrypsin deficiency.  The antibody only recognised α1-antitrypsin 
polymers in plasma, and not other proteins, as immunoprecipitation yielded a single band of α1-
antitrypsin from plasma containing polymer but no protein from plasma with no polymers (Fig. 1b). 
 
Clearance of polymers following liver transplantation 
Plasma levels of α1-antitrypsin were low in the PiZZ α1-antitrypsin homozygote described in the 
case report but rose from 0.2 mg/mL to 2.1 mg/mL following hepatic transplantation.  Circulating α1-
antitrypsin polymers were detected in this individual prior to transplantation but fell rapidly following 
the procedure (Fig. 2A).  This may in part relate to the requirement for intra-operative haemodialysis.  
The levels continued to fall in the post-operative phase.  Fitting the post-operative decline to an 
exponential decay function allowed an estimate for the half-life of circulating polymers as 30 hours 
(Fig. 2B).  The level of circulating polymers became undetectable after 4 days (lower limit of 
quantification of polymers 0.4 µg/mL) demonstrating that they arise from Z α1-antitrypsin synthesised 
within the liver. 
 
The correlation of circulating polymers with clinical phenotypes (cohort 2) 
Cohort 2 was used to establish whether there was a correlation between circulating polymers of α1-
antitrypsin and various clinical phenotypes in individuals with α1-antitrypsin deficiency.  Polymer 
levels were measured in blood samples from 244 confirmed PiZZ α1-antitrypsin homozygote subjects 
who had never received augmentation therapy.  No subjects had undergone liver or lung 
transplantation.  Demographic details and smoking history were recorded at the time of enrolment to 
the study (Table 1A).  Pre-bronchodilator spirometric data were available on 239 subjects with 90 
subjects being defined as having COPD based on a pre-bronchodilator FEV1/FVC<70% and 
FEV1<80% predicted (Table 1B).  Post-bronchodilator spirometry was available on 230 of the overall 
subjects and 87 of the subjects with COPD; of the COPD subjects the mean pre and post 
bronchodilator FEV1 were 53.4 (SD 19.1) and 57 (20.4) % predicted respectively and the mean pre 
and post bronchodilator FEV1/FVC were 0.52 (0.16) and 0.53 (0.17).  The pre-bronchodilator 
spirometry values were used in order to maximise the number of subjects in the analysis.  Circulating 
polymers were detected in all 244 individuals with PiZZ α1-antitrypsin deficiency with concentrations 
ranging from 8.2 to 230.2 µg/mL.  The mean concentration of α1-antitrypsin polymers in the 244 
subjects was 36.3 µg/mL (SD 33.3).  Levels were higher in males (mean 42.8 µg/mL, range 8.2-230.2) 
compared to females (mean 32.2 µg/mL, range 8.2-183.0; p=0.02) and were higher in subjects with 
COPD (42.6 µg/mL versus 32.5 µg/mL, p=0.02).  Univariate analysis revealed an association between 
polymer concentration and FEV1/FVC (-0.411 SE 0.116, p<0.0005; Table 2) but no association 
between ever-smoking history, pack-years of smoking or age started smoking.  A multivariate model 
with and without adjustment for FEV1 was evaluated including sex and age.  Sex remained a robust 
predictor of polymer level after adjustment for age, ever-smoking and FEV1 (p≤0.01 for sex for all 
models).  The total R2 of the full model with age, sex and FEV1 was 0.19 suggesting that other 
unmeasured covariates likely impact on the circulating level of α1-antitrypsin polymers.  There was no 
significant age by sex interaction (p>0.10, data not shown).  In an unadjusted logistic model predicting 
COPD, each unit increase in log transformed polymer level was associated with higher odds for 
COPD (OR 3.8, 95% confidence interval 1.6-9.3); once adjusted for smoking there still remained an 
association between each unit increase in log transformed polymer level and COPD (OR 3.6, 95% 
confidence interval 1.4-9.1). 
The Alpha-1 Antitrypsin Genetic Modifier Study Cohort was not ascertained to assess liver disease 
and therefore analysis of the liver specific questions must be considered to be exploratory.  Polymer 
levels were evaluated in data parsed by responses to self-reported histories of abnormal liver function 
tests, physician-confirmed cirrhosis, physician-confirmed liver disease, hepatitis, neonatal jaundice 
and any jaundice.  Approximately 15.6% of subjects answered ‘yes’ to a question about ever having 
abnormal liver function tests, 9% reported neonatal jaundice and 3% had physician-confirmed liver 
disease or cirrhosis.  In all cases, a self-report of ‘yes’ to any of these questions was associated with 
higher polymer levels in the 244 PiZZ α1-antitrypsin subjects (Table 3).  6.4% of men self-reported a 
physician-confirmed history of liver disease compared with 1.3% of women; 5.3% of men and 2.7% 
of women reported physician-confirmed cirrhosis.  Males had higher circulating levels of α1-
antitrypsin polymers than females in all instances of “no” answers to liver disease questions.   
Interestingly, although the numbers are small and the results not statistically significant, the mean 
polymer level for individuals with physician-confirmed cirrhosis and liver disease and reports of 
abnormal liver tests were higher in women than men.  This was the only instance in which women had 
higher polymer levels than men (Table 3). 
 
 
Discussion 
 
Our previous work has shown that mutant Z α1-antitrypsin forms polymers that accumulate as 
Periodic Acid Schiff (PAS) positive inclusions within hepatocytes [3].  These polymers are also 
present within the skin [9], kidney [10] and lung [5-8, 16].  We report here the use of a novel anti-α1-
antitrypsin polymer monoclonal antibody (2C1) to evaluate the presence of polymers in the plasma of 
individuals with α1-antitrypsin deficiency.  Circulating polymers were present in all individuals with 
PiZZ α1-antitrypsin deficiency.  The presence of polymers was 100% sensitive in identifying PiZZ α1-
antitrypsin homozygotes in a mix of other genotypes.  Polymers were also detected in individuals who 
were heterozygous for Z and another allele (M, S, Mmalton and Mheerlen).  One PiMM α1-antitrypsin 
individual had a low signal for circulating polymers but they were not detected in the other 199 
individuals with a normal α1-antitrypsin phenotype.  We have shown that severe deficiency alleles 
such as: Mmalton (52Phe del) [17], Siiyama (Ser53Phe) [18] and King’s (His334Asp) [12] α1-
antitrypsin also form polymers.  The mild deficiency alleles S (Glu264Val) [19] and I (Arg39Cys) 
[20] α1-antitrypsin similarly form polymers but at a slower rate in keeping with less retention in the 
liver, a lack of inclusions and milder plasma deficiency.  This is in keeping with the absence of 
circulating polymers in the 3 PiSS α1-antitrypsin individuals in this study.  The epitope recognised by 
the 2C1 anti-polymer antibody is unknown but in vitro studies have shown it to be polymer specific 
irrespective of the underlying mutation in the α1-antitrypsin gene [12].  It will therefore detect 
circulating polymers generated from other polymer forming alleles.  This may represent a useful 
biomarker for α1-antitrypsin deficiency.  However the specificity is reduced as one individual with a 
normal PiMM α1-antitrypsin phenotype also had low circulating level of polymers.  Moreover 
individuals with rare Null alleles will not have circulating polymers as there is no secreted gene 
product.  
Polymers of α1-antitrypsin are present within the lungs of individuals with α1-antitrypsin deficiency 
[5-7].  They are pro-inflammatory for human neutrophils in vitro [6, 16] and following their 
instillation into the lungs of mice [7].  Moreover cigarette smoke induces both intrapulmonary 
polymer formation and neutrophil influx in transgenic mice that express Z, but not M α1-antitrypsin 
[8].  It was therefore important to assess whether the circulating levels of polymers correlated with any 
demographic factor or clinical outcome in α1-antitrypsin deficiency.  Our data show that there was a 
relationship between circulating levels of polymer and male gender.  There were also associations 
between FEV1/FVC (which correlates closely with emphysema [21]) and with the presence of COPD.  
Thus circulating polymers may be causal in the pathogenic pathway of lung function decline and 
emphysema in individuals with α1-antitrypsin deficiency.  The association between sex and levels of 
polymers was seen in all analyses with the possible exception of individuals with liver disease.  The 
cause of this is unclear but previous studies have shown that treatment with the synthetic androgen, 
Danazol, raised levels of α1-antitrypsin in individuals with α1-antitrypsin deficiency [22].  Thus sex 
hormones may also be important in driving the production of circulating polymers. 
Alpha-1-antitrypsin is largely secreted from the liver.  It is also synthesized in the bronchial 
epithelial cells where it contributes to the local production of polymers [6].  α1-antitrypsin is also 
synthesized in the gut [23], in circulating monocytes [24] and tissue macrophages [25].  In all cases 
α1-antitrypsin from PiZZ homozygotes has the propensity to form polymers and so may contribute to 
the circulating levels detected in these individuals.  However the observation that circulating polymers 
become undetectable following hepatic, but not lung transplantation (data not shown), demonstrates 
that they arise from α1-antitrypsin that is synthesised in the liver.  The estimate of the half-life of 
polymer clearance of 30 hours should be interpreted with caution as the individual undergoing 
transplantation required intraoperative haemodialysis and will have received blood products 
containing α1-antitrypsin.   The association of circulating polymers with liver disease in cohort 2 can 
only be considered as exploratory and was not significant.  Nevertheless our findings provide support 
for further studies to evaluate this biomarker in longitudinal studies of liver disease in individuals with 
PiZZ α1-antitrypsin deficiency. 
Taken together, our data show that circulating polymers are present in all individuals with PiZZ α1-
antitrypsin deficiency and that they are associated with lung, and possibly liver disease.  Further 
studies are now required to establish the temporal stability of circulating polymers and whether this 
biomarker has utility in predicting clinically important outcomes in individuals with PiZZ α1-
antitrypsin deficiency.  However, this polymer-based biomarker will be useful to monitor the efficacy 
of small molecules designed to block polymerisation should the current lead molecules progress to 
clinical trials [26]. 
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A. 
Characteristic All (N=244) Male (N=94) Female (N=150) 
Age 50.5 (9.7) 50.2 (9.1) 50.6 (10.1) 
FEV1 % predicted* 83.9 (28.2) 72.8 (30.6) 90.9 (24.2) 
FEV1/FVC* 0.67 (0.17) 0.61 (0.18) 0.70 (0.14) 
COPD (%) 90 (36.9) 50 (53.2) 40 (26.7) 
Current smokers (%) 8 (3.3) 3 (3.2) 5 (3.3) 
Ever-smokers (%) 106 (43.4) 43 (45.7) 63 (42) 
Pack-years* 13.4 (13.3) 15.6 (14.3) 11.8 (12.4) 
Polymer levels, µg/mL 36.3 (33.3) 42.8 (37.6) 32.2 (29.8) 
 
B. 
Characteristic All (N=90) Male (N=50) Female (N=40) 
Male (%) 50 (55.6) 50 40 
Age 53.1(10.4) 52.2(9.1) 54.1(11.9) 
FEV1 % predicted* 53.4 (19.1) 49.4(20.5) 58.5(16.2) 
FEV1/FVC* 0.52(0.15) 0.50(0.16) 0.55(0.15) 
Current smokers (%) 4(4.4) 1(2.0) 3(7.5) 
Ever-smokers (%) 51(56.7) 29(58.0) 22(55.0) 
Pack-years  16.9(14.2) 18.6(15.5) 14.8(12.4) 
Polymer levels (µg/mL) 42.6(37.2) 45.9(37.5) 38.6(36.8) 
 
Table 1.  A (above) Characteristics of 244 PiZZ α1-antitrypsin subjects and B (below) the 90 
individuals with COPD.  The values are number and percentage or mean and standard deviation.  
*Spirometric values are pre-bronchodilator; pack-years are reported for ever and current smokers. 
 
 Predictor Regression coefficient (SE) P value 
Sex 0.121 (0.039) 0.0022 
Age 0.012 (0.002) <0.0001 
Ever smoking -0.005 (0.039) 0.9086 
Pack-years 0.003 (0.002) 0.2064 
FEV1 -0.003 (0.001) 0.0003 
FEV1/FVC -0.411 (0.116) 0.0005 
 
Table 2.  Univariate models predicting log transformed polymer concentration in the 244 PiZZ α1-
antitrypsin subjects.  Females are the reference group for sex, never smoker is the reference group for 
ever smoking. 
 
 
 Characteristic All (N=244) Polymer level (µg/mL)-
Yes 
Polymer level (µg/mL)- 
No 
Abnormal liver tests 38 (15.6%) 44.4 (35.6) 34.7 (32.8) 
Confirmed cirrhosis 9 (3.7%) 61.1 (40.3) 35.3 (32.8) 
Confirmed liver disease 8 (3.3%) 51.0 (37.4) 35.8 (33.2) 
Hepatitis 12 (4.9%) 62.4 (67.9) 34.9 (30.2) 
Neonatal jaundice 22 (9.0%) 43.1 (35.5) 35.6 (33.1) 
Any jaundice 23 (9.4%) 54.9(51.0) 34.3 (30.5) 
  
Males 
Characteristic All (N=94) Polymer level (µg/mL)-
Yes 
Polymer level (µg/mL)- 
No 
Abnormal liver tests 18 (19.1%) 42.8 (25.9) 42.8 (40.0) 
Confirmed cirrhosis 5 (5.3%) 58.2 (43.0) 41.9 (37.4) 
Confirmed liver disease 6 (6.4%) 36.9 (26.0) 43.2 (38.3) 
Hepatitis 4 (4.3%) 78.8 (102.7) 41.2 (32.6) 
Neonatal jaundice 9 (9.6%) 53.6 (38.7) 41.6 (37.5) 
Any jaundice 9 (9.6%) 72.0 (67.3) 39.7 (32.1) 
 
Females 
Characteristic All (N=150) Polymer level (µg/mL)-
Yes 
Polymer level (µg/mL)- 
No 
Abnormal liver tests 20 (13.3%) 45.9 (43.2) 30.1 (26.8) 
Confirmed cirrhosis 4 (2.7%) 64.6 (42.8) 31.3 (29.0) 
Confirmed liver disease 2 (1.3%) 93.1 (40.5) 31.3(28.9) 
Hepatitis 8 (5.3%) 54.2 (49.9) 30.9 (28.0) 
Neonatal jaundice 13 (8.7%) 35.8 (32.7) 31.8 (29.6) 
Any jaundice 14 (9.3%) 43.9 (35.8) 31.0 (29.0) 
 
Table 3.  Exploratory analysis of liver disease in 244 PiZZ α1-antitrypsin subjects.  The values are 
number and percentage or mean and standard deviation. 
 80#
60#
40#
20#
!!ZZ!!!!!!!!!!!!!MZ!!!!!!!!!!!!SZ!!!!!!!!!!!!!!FZ !!!!!ZMmalton!!ZMheerlen!!!!SS!!!!!!!!!!MS!!!!!!!!!MM!!
!!20/20!!!!!!!!!!!!!!7/20!!!!!!!!!!!!!14/20!!!!!!!!!!!!!!3/5 !!!!!!2/2!!!!!!!!!!!!!!!!3/3!!!!!!!!!!!!!!!!!!!!0/3!!!!!!!!!!!!1/20!!!!!!!!!!!1/!200
Po
ly
m
er
#C
on
ce
nt
ra
3o
n#
(µ
g/
m
l)#
1#
205#
 
 
 
 
 
 
 
Figure 1.  Detection of α1-antitrypsin polymers in plasma.  Fig. 1a.  Concentration of serum α1-
antitrypsin polymers in 293 individuals with a mix of α1-antitrypsin genotypes.  The values below the 
genotypes are the number of subjects with detectable levels of circulating polymers (lower limit of 
quantification of polymers 0.4 µg/mL).  Fig 1b.  The 2C1 monoclonal antibody immunoprecipitated 
only α1-antitrypsin from the plasma of an individual who had a positive signal on ELISA.   Lane 1, 
Purified M α1-antitrypsin control; lane 2, purified Z α1-antitrypsin control; lane 3, α1-antitrypsin 
immunoprecipitated with the 2C1 monoclonal antibody from the plasma of a PiMM individual with no 
polymers on ELISA; lane 4, α1-antitrypsin immunoprecipitated with the 2C1 monoclonal antibody 
from the plasma of a PiZZ individual with a positive signal for polymers on ELISA; lane 5, sepharose 
G beads incubated with 2C1 without adding plasma sample (IP-ctrl); lane 6, sepharose G beads alone 
(IP-beads); lane 7, 2C1 antibody alone (2C1-ctrl).  
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Figure 2.  Z α1-antitrypsin polymers are present in the circulation and are cleared following liver 
transplantation.  (A) Serum α1-antitrypsin was quantified using sandwich ELISA.  Mouse monoclonal 
antibodies produced by our group that detect all conformers of α1-antitrypsin, or only polymeric α1-
antitrypsin (2C1 [12, 13]), were used to quantify total α1-antitrypsin and α1-antitrypsin polymers 
respectively.  Time points marked * are below the lower limit of quantification (0.4 µg/mL).  (B) 
Estimation of Z α1-antitrypsin polymer t1/2 using t1/2 = ln2/λ.  The pre-transplant sample was excluded 
in view of the requirement for intra-operative hemofiltration. 
 
